PARIS – L’Oréal has bought inexperienced magnificence model Sanoflore to French funding fund Ekkio Capital and Sergio Calandri, Sanoflore’s new chief govt officer, who can also be the founding father of Inula Group, which has different pure product manufacturers.
“L’Oréal has a portfolio of complimentary manufacturers. The group’s technique is to accumulate and, generally, exit, the manufacturers, to maintain a really sturdy portfolio and the complementarity it must thrive over the long run,” the group mentioned in a press release.
“The success of L’Oréal Dermatological Magnificence relies on a method and a enterprise mannequin centered on manufacturers prescribed by healthcare professionals,” the group continued. “Beneath these situations, the division has determined to concentrate on the dermatological manufacturers in its portfolio.”
Ekkio Capital makes a speciality of small and medium-size corporations within the well being and wonder area. Calandri’s Inula Group contains manufacturers HerbalGem and Biofloral.
“This sale doesn’t lead to any redundancies in France,” L’Oréal mentioned, including that it ”helps every of the staff involved with profession improvement tailor-made to their abilities. The model’s exterior companions are additionally supported, in step with our group’s sturdy social values.”
L’Oréal acquired Sanoflore in October 2006, the identical yr it bought pure magnificence maker and retailer The Physique Store, which it subsequently bought. On the time, business watchers believed it heralded in a seismic shift within the magnificence business towards inexperienced cosmetics, which turned out to be the case.
On the time, Sanoflore, primarily based within the Drome area of southeast France, was already 20 years outdated. The model based by Fodolphe Balz was then added to what was then known as L’Oréal’s Lively Cosmetics division. The group’s plan was to capitalize on client demand for natural merchandise and increase Sanoflore’s worldwide attain.
L’Oréal Dermatological Magnificence division contains manufacturers equivalent to La Roche-Posay, Vichy and CeraVe. Within the second quarter of 2023, the department’s gross sales reached 1.6 billion euros, a 27.3 % rise versus the identical prior-year interval.
